Biologic Specimen Management Core

生物样本管理核心

• 批准号: 7786699
• 负责人: Shelley S Tworoger
• 金额: $ 48.88万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2015-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7786699
• 关键词: Arts; Biological; Biological Assay; Biological Markers; Blood specimen; Breast; Cancer Etiology; Cells; Cheek structure; Cohort Studies; Collection; Colon; Colorectal; DNA; Development; Disease; Ensure; Epidemiologic Studies; Erythrocytes; Ethics; Evaluation; Genetic; Genus Cola; Goals; Laboratories; Lead; Life Style; Maintenance; Malignant Neoplasms; Malignant neoplasm of ovary; Mammographic Density; Mammography; Management Information Systems; Measures; Methodology; Methods; Molecular; Nested Case-Control Study; Nurses' Health Study; Participant; Pilot Projects; Plasma; Preparation; Prevention; Procedures; Process; Quality Control; Reproducibility; Research; Resources; Risk Factors; Sampling; Specimen; Specimen Handling; Time; Tissues; Tumor Tissue; Urine; Woman; biobank; cancer risk; cost; epigenetic variation; follow-up; improved; malignant breast neoplasm; prospective; repository

The Nurses' Health Study (NHS), as well as the NHSII (used in Project 3), are prospective cohort studies of about 238,000 women. A unique aspect of the studies are the collection of biologic specimens that can be used to further elucidate molecular mechanisms of disease through examination of genetic and epigenetic variation, circulating biomarkers, and tumor tissue markers. We have collected blood samples on over 60,000 women, urine for nearly 50,000 women, cheek cell DNA for over 60,000 women without blood samples, and thousands of tumor tissue blocks. These samples are a valuable but finite resource, thus we put substantial effort into ensuring high quality and efficient specimen handling and piloting new assay methodology in a cost-effective, ethical, state of the art manner. The aim of the Biologic Specimen Management Core (Core C) is to collect, store, process, and distribute biological specimens from women in the NHS/NHSII to better understand the etiology of cancer. Specifically, we aim to provide biologic specimens, including plasma, urine, buffy coat, red blood cells, and cheek cell DNA, for nested case-control studies of breast, colorectal, and ovarian cancers through the NHS Biomarker Laboratory and Repository. Further we will provide tumor tissue for studies of breast, colorectal, and ovarian cancer, as well as mammographic density measures for breast cancer, and to collect and process related specimens via the NHS Tissue and Mammogram Repository. To support these repositories we will maintain and improve an over-arching project management and sample tracking laboratory information management system (LIMS). Central activities of this core include collection of new specimens, processing of samples, management and maintenance of related biorepositories, and preparation of specimens for assay. Importantly, the core conducts pilot studies of all new assays to ensure high reproducibility before sending participant specimens for analysis; quality control procedures also allow for real-time tracking of assay quality while participant samples are being analyzed. Notably, this Core supports scientific aims in Projects 1 -4 of the current application.

护士健康研究（NHS）以及NHSII（项目3）是对约238,000名妇女的前瞻性队列研究。研究的一个独特方面是收集生物标本，可通过检查遗传和表观遗传变异，循环生物标志物和肿瘤组织标记来进一步阐明疾病的分子机制。我们已经收集了60,000多名女性的血液样本，近50,000名女性的尿液，有60,000多名没有血液样本的女性的脸颊细胞DNA以及数千个肿瘤组织块。这些样本是一个有价值但有限的资源，因此我们 在确保以具有成本效益，道德和最先进的状态的高质量和高效标本处理和试行新测定方法方面付出了巨大的努力。 生物标本管理核心（Core C）的目的是收集，存储，处理和分发来自NHS/NHSII女性的生物标本，以更好地了解癌症的病因。具体而言，我们旨在通过NHS Biomarker Laboratory and Reposoritor和卵巢癌进行嵌套的病例对照研究，以提供生物学标本，包括血浆，尿液，红细胞，红细胞和脸颊细胞DNA。此外，我们将提供肿瘤组织，用于研究乳腺癌，结直肠癌和卵巢癌，以及乳腺癌的乳腺X线摄影密度测量，并收集和过程相关 通过NHS组织和乳房X线图存储库标本。为了支持这些存储库，我们将维护并改善整个项目管理和样本跟踪实验室信息管理系统（LIMS）。该核心的中心活动包括收集新标本，处理样品的处理，相关生物膜的管理和维护以及准备测定标本的准备。重要的是，核心对所有新测定法进行试点研究，以确保在发送参与者标本进行分析之前确保高可重现性。质量控制程序还可以在分析参与者样本的同时实时跟踪测定质量。值得注意的是，该核心支持科学目标在当前应用程序的第1-4个项目中。